Maria de Fátima Borges

Maria de Fátima Borges

Auto-generated profile, based on publicly available information

Maria de Fátima Borges

Universidade Federal do Triângulo Mineiro image/svg+xml

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2018 in Clinical Epigenetics
Verified
Journal Article
Open access
PDF file
DBDanielle S. Bessa
Danielle S. Bessa
Mariana MaschiettoMariana Maschietto
Mariana Maschietto
CACarlos Francisco Aylwin
Carlos Francisco Aylwin
ACAna P. M. Canton
Ana P. M. Canton
VBVinicius N. Brito
Vinicius N. Brito
ALAna Claudia Latronico
Ana Claudia Latronico
Recent studies demonstrated that changes in DNA methylation (DNAm) and inactivation of two imprinted genes (MKRN3 and DLK1) alter the onset of female puberty. We aimed to investigate the association of DNAm profiling with the timing of human puberty analyzing the genome-wide DNAm patterns of peripheral blood leukocytes from ten female patients with central precocious puberty (CPP) and 33 healthy girls (15 pre- and 18 post-pubertal). For this purpose, we performed comparisons between the groups: pre- versus post-pubertal, CPP versus pre-pubertal, and CPP versus post-pubertal. Analyzing the methylome changes associated with normal puberty, we identified 120 differentially methylated regions (DMRs) when comparing pre- and post-pubertal healthy girls. Most of these DMRs were hypermethylated in the pubertal group (99%) and located on the X chromosome (74%). Only one genomic region, containing the promoter of ZFP57, was hypomethylated in the pubertal group. ZFP57 is a transcriptional repressor required for both methylation and imprinting of multiple genomic loci. ZFP57 expression in the hypothalamus of female rhesus monkeys increased during peripubertal development, suggesting enhanced repression of downstream ZFP57 target genes. Fourteen other zinc finger (ZNF) genes were related to the hypermethylated DMRs at normal puberty. Analyzing the methylome changes associated with CPP, we demonstrated that the patients with CPP exhibited more hypermethylated CpG sites compared to both pre-pubertal (81%) and pubertal (89%) controls. Forty-eight ZNF genes were identified as having hypermethylated CpG sites in CPP. Methylome profiling of girls at normal and precocious puberty revealed a widespread pattern of DNA hypermethylation, indicating that the pubertal process in humans is associated with specific changes in epigenetically driven regulatory control. Moreover, changes in methylation of several ZNF genes appear to be a distinct epigenetic modification underlying the initiation of human puberty.

1 January 2016 in Clinics
Verified
Journal Article
Open access
MBMaria de Fátima Borges
Maria de Fátima Borges
FTFlávia Carolina Cândida Teixeira
Flávia Carolina Cândida Teixeira
AFAline Karin Feltrin
Aline Karin Feltrin
KRKarina Alvarenga Ribeiro
Karina Alvarenga Ribeiro
GNGabriel Antonio Nogueira Nascentes
Gabriel Antonio Nogueira Nascentes
HPHeloísa Marcelina Cunha Palhares
Heloísa Marcelina Cunha Palhares
To establish cut-off values for growth hormone concentrations using clonidine as a secretagogue and an immunochemiluminescent assay as the method of measurement and to analyze the response time as well as the influence of gender, nutritional status and pubertal stage. A total of 225 tests were performed in 3 patient groups, categorized as group 1 (normal), group 2 (idiopathic short stature) and group 3 (growth hormone deficiency). Among the 199 disease-free individuals, 138 were prepubertal, and 61 were pubertal. Clonidine (0.1 mg/m2) was orally administered, and the growth hormone level was measured by immunochemiluminescent assay. The growth hormone peak and the difference between the growth hormone peak and the baseline level were then analyzed. Statistical analyses were performed using Student's t-test or the Mann-Whitney test and Kruskal-Wallis test followed by Dunn's post hoc test. Cut-off values were determined using a receiver operating characteristic curve. Group 1 and group 2 had no difference in growth hormone peak, gender, body mass index standard deviation score, or pubertal stage. Group 3 exhibited a significantly lower growth hormone peak than the other groups did. The receiver operating characteristic curve demonstrated that growth hormone concentrations ≥ 3.0 ng/mL defined responsiveness to clonidine. In total, 3.02% of individuals in group 1 and group 2 were considered false positive, i.e., these children lacked growth hormone deficiency and had a peak below 3.0 ng/mL. Clonidine-stimulated growth hormone concentrations ≥3 ng/mL, as measured by immunochemiluminescent assay, suggest responsiveness to the stimulus regardless of gender, body mass index standard deviation score or pubertal stage.

1 January 2019 in Clinics
Verified
Journal Article
Open access
FRFlávia Alves Ribeiro
Flávia Alves Ribeiro
ERElisabete Aparecida Mantovani Rodrigues de Resende
Elisabete Aparecida Mantovani Rodrigues de Resende
ASAdriana Paula da Silva
Adriana Paula da Silva
JTJanaíne Machado Tomé
Janaíne Machado Tomé
HPHeloísa Marcelina da Cunha Palhares
Heloísa Marcelina da Cunha Palhares
MBMaria de Fátima Borges
Maria de Fátima Borges
Follow-up studies of girls with premature adrenarche have reported the development of polycystic ovary syndrome, insulin resistance, and dyslipidemia and a propensity to cardiovascular disease. The aim of this study was to analyze the presence of these conditions in patients previously treated at the Universidade Federal do Triângulo Mineiro. A total of 130 medical records reported premature adrenarche. One hundred and twenty-two patients were invited to participate, of whom 54 accepted; 34 patients were selected, as they had reached their final height. Anthropometric, blood glucose, insulin, and lipid and hormonal profile (LH, FSH, estradiol, 17α-OH-progesterone, androstenedione, dehydroepiandrosterone sulfate, testosterone) data were obtained, the HOMA-IR index was calculated, and pelvic ultrasonography was performed. To characterize polycystic ovary syndrome and metabolic syndrome, the Rotterdam and International Diabetes Federation criteria, respectively, were used. Data were analyzed according to measures of dispersion, frequency and correlations of interest. The age of the participants ranged from 15.2 to 28.2 years/months; 23.5% of the patients were overweight, 11.8% were obese, 29.4% had a large waist circumference, and 8.8% were hypertensive. None of the patients had altered glucose levels, and insulin levels and HOMA-IR were elevated in 29.4% and 38.2% of the participants, respectively; 14.7% of the patients exhibited acanthosis nigricans. The lipid profiles of the participants were variable, and one patient (2.9%) had metabolic syndrome. Polycystic ovary syndrome was found in 41.2% of patients. The percentage of patients with polycystic ovary syndrome who also had overweight, obesity and insulin resistance corroborates the literature data about the need for follow-up aiming at interventions, especially for conditions associated with cardiometabolic risk.

1 February 2008 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
MBMaria F. Borges
Maria F. Borges
AOAndréia A. Oliveira
Andréia A. Oliveira
CRCláudia V. C. Rita
Cláudia V. C. Rita
KPKarla D. Pacheco
Karla D. Pacheco
ERElisabete A. M. Resende
Elisabete A. M. Resende
BFBeatriz P. Ferreira
Beatriz P. Ferreira
In order to establish cut-off limits and to distinguish isolated premature thelarche (IPT) from precocious puberty (PP), we evaluated data from 79 girls with premature thelarche, comparing basal and stimulated LH and FSH serum concentrations with those from 91 healthy girls. A GnRH stimulation test was performed in 10 normal girls and in 42 with premature thelarche. Comparison among groups was performed by Kruskal-Wallis and Dunn’s tests. LH values were significantly greater in girls with IPT than in control groups. Basal gonadotropin concentrations were higher in patients with PP than in controls, but not different from patients with IPT. Peak LH levels after GnRH stimulation distinguished those two groups, with a cut-off value of 4.0 IU/L, but still with minimal overlap. In conclusion, a girl with premature thelarche and LH peak value above 4.5 IU/L has, indeed, PP, but values between 3.5 and 4.5 IU/L point to careful follow-up.

1 October 1999 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
BJBeatriz H. Jorge
Beatriz H. Jorge
MBMaria de Fátima Borges
Maria de Fátima Borges
VBVinícius N. de Brito
Vinícius N. de Brito
TSThessa G.M. dos Santos
Thessa G.M. dos Santos
ATAna Cláudia P. Thirone
Ana Cláudia P. Thirone
O presente trabalho tem como objetivo analisar 70 pacientes diabéticos portadores de lesões podais infectadas, internados para tratamento no Hospital Escola da Faculdade Federal de Medicina do Triângulo Mineiro no período compreendido entre 1989 e 1998. As lesões foram analisadas considerando-se o tipo de diabetes mellitus (DM) apresentado pelo paciente, tempo decorrido entre o diagnóstico de DM e a internação, agentes etiológicos mais freqüentemente encontrados nas culturas das secreções, tipo de tratamento requerido e evolução clínica dos pacientes. A maioria dos pacientes estudados (87%) era portadora de DM tipo 2. Não se observou diferença estatística quanto ao sexo, com predomínio nas 6ª e 7ª décadas de vida. As lesões foram mais freqüentes nos pacientes com mais de 5 anos de diagnóstico de DM. As bactérias mais comumente encontradas nas culturas das secreções foram Proteus mirabilis e Staphylococcus sp. Os pacientes receberam terapia antibiótica específica, curativos diários e desbridamentos, quando necessários. Sessenta e um por cento dos pacientes requererem amputação e 15,7% foram a óbito por septicemia. As internações foram prolongadas, com duração média de 38 dias. As lesões podais em pacientes diabéticos são um grande problema de saúde pública. O tratamento é prolongado, podendo trazer mudanças drásticas na qualidade de vida dos pacientes. A prevenção ainda é a melhor maneira de combatermos este problema.

1 December 2015 in Archives of Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
MBMaria de Fátima Borges
Maria de Fátima Borges
PFPriscila de Melo Franciscon
Priscila de Melo Franciscon
TCThamy Contursi Cambraia
Thamy Contursi Cambraia
DODébora Matias Oliveira
Débora Matias Oliveira
BFBeatriz Pires Ferreira
Beatriz Pires Ferreira
HPHeloísa Marcelina Cunha Palhares
Heloísa Marcelina Cunha Palhares
Key words: GnRH analogue; final stature; target stature; precocious central idiopathic puberty; precocious puberty